Literature DB >> 9491556

Enantioselective determination of terazosin in human plasma by normal phase high-performance liquid chromatography-electrospray mass spectrometry.

A P Zavitsanos1, T Alebic-Kolbah.   

Abstract

A sensitive and selective analytical method for the enantioselective determination of terazosin in human plasma has been developed. The chromatography is based on the normal-phase chiral separation utilizing the analogue prazosin as the internal standard. The detection involves the direct introduction of the normal-phase eluent into an electrospray source followed by mass-selective detection. No pre-column derivatization was required prior to analysis. The chiral stationary phase used was Chiralpak AD 100 mm x 2.1 mm I.D. (10 microns particle size). The method was utilized to determine the concentrations of terazosin enantiomers in human subjects following a 5 mg single oral dose. Results were compared with those from an enantioselective HPLC-fluorescence method from the same subject plasma samples. The LC-MS results confirm with confidence that the two terazosin enantiomers have different elimination profiles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491556     DOI: 10.1016/s0021-9673(97)00892-3

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  3 in total

1.  Sensitive determination of terazosin in pharmaceutical formulations and biological samples by ionic-liquid microextraction prior to spectrofluorimetry.

Authors:  Mohsen Zeeb; Mahdi Sadeghi
Journal:  Int J Anal Chem       Date:  2012-02-08       Impact factor: 1.885

2.  Asymmetric reduction of ketones and β-keto esters by (S)-1-phenylethanol dehydrogenase from denitrifying bacterium Aromatoleum aromaticum.

Authors:  A Dudzik; W Snoch; P Borowiecki; J Opalinska-Piskorz; M Witko; J Heider; M Szaleniec
Journal:  Appl Microbiol Biotechnol       Date:  2014-12-31       Impact factor: 4.813

3.  Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical Formulations.

Authors:  Alankar Shrivastava; Vipin B Gupta
Journal:  Sci Pharm       Date:  2012-05-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.